University of Ioannina
Πεπτιδικά ανάλογα του αιμοπεταλιακού υποδοχέα IIb/IIIa: Επίδραση σε πειραματικά μοντέλα αρτηριακής θρόμβωσης
Abstract
dc:descriptionInhibition of platelet aggregation has been identified as a promising target for the development of new antiplatelet and antithrombotic drugs in acute coronary syndromes. We have recently identified a synthetic peptide, YMESRADR, corresponding to amino acid residues 313- 320 of the αΙΙβ subunit of platelet integrin αΙΙbβ3 that exhibits potent antiplatelet activity, in vitro. We studied the peptide’s effect on experimental thrombosis in rabbits. The animals were divided in groups (n=5 in each group) receiving intravenously a. normal saline, 6 ml/kg/h (control group), b. YMESRADR, to doses pf 3, 7.5 38 and 50 mg/kg, c. heparin 100 IU/kg/h and d. eptifibatide in two different doses: 180 μg/kg bolus plus 2 μg/kg/min (low dose) and 900 μg/kg bolus plus 10 μg/kg/min (high dose). Carotid artery thrombus formation (under continuous blood flow monitoring) was induced by electrical stimulation. Ex vivo platelet aggregation to 20 μM ADP in platelet rich plasma (PRP) and coagulation assays (thrombin time, TT; prothrombin time, PT; activated partial thromboplastin time, aPTT; fibrinogen and XIII factor levels) were determined before (baseline) and at 60 min after the initiation of drug administration (instantly prior to electrical stimulation). Ninety minutes after electrical stimulation the carotid thrombus was removed and weighed. Blood loss was calculated by the amount of blood, gathered on a pre-weighed gauge, positioned on a standardized incision, performed on the anterior abdominal wall. In the control group, carotid artery was totally occluded within 23.3±3.2 min after electrical stimulation. By contrast, in the YMESRADR (50mg), heparin and eptifibatide groups, carotid artery blood flow at 90 min after electrical stimulation, was reduced to 23,9±0,9%, 26,3%±12,7% and 36,9±5,0% (low dose), 35,3±5,1% (high dose) respectively (p<0.001 over control). Similarly, thrombus weight was significantly reduced in animals receiving YMESRADR (50 mg), heparin or eptifibatide over control: 1,66±1,18mg, 3,92±0,74mg and 1,72±0,58 mg (low dose), 2,1±1,1 mg (high dose) versus 5,72±0,86mg respectively, (p<0.003 over control). Platelet maximum aggregation to ADP in the control group, 60 min after electrical stimulation, was not altered compared to baseline, whereas it was significantly reduced by 34,3±14,5%, 28,0±6,6% (low dose), 38,3±11,0% (high dose) in the YMESRADR (15 mg/kg) and eptifibatide groups respectively, (p<0.004). There were no significant variations regarding blood loss and coagulation assays in the eptifibatide and YMESRADR groups compared to control group. We show for the first time that similarly to eptifibatide, YMESRADR reduces experimental thrombus formation in rabbits by inhibiting platelet aggregation, without influencing the blood coagulation parameters.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2009
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papamichael, Nikolaos
- Παπαμιχαήλ, Νικόλαος
Subjects
dc:subject × 20- Αιμοπετάλια
- Αρτηριακή θρόμβωση
- Αιμοπεταλιακός υποδοχέας
- Πειραματικά μοντέλα
- Κουνέλια
- Αιμοπεταλιακή ιντεγκρίνη
- Αντιαιμοπεταλιακά φάρμακα
- Πεπτίδια
- Platelets
- Arterial thrombosis
- Platelet receptor
- Experimental model
- Rabbits
- Platelet integrin
- Antiplatelet drugs
- Peptides
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/27179